75 results about "Senile macular degeneration" patented technology

Surgical apparatus and surgical methods are proposed for the prevention of age-related macular degeneration (AMD) and choroidal neovascularization (CNV), and other eye diseases such as glaucoma by removal of the sclera tissue to reduce its rigidity and increase the flood flow and decrease pressure in the choriocapillaris. The disclosed preferred embodiments of the system consists of a tissue ablation means and a control means of ablation patterns and a fiber delivery unit. The basic laser beam includes UV lasers and infrared lasers having wavelength ranges of (0.15-0.36) microns and (0.5-3.2) microns and diode lasers of about 0.98, 1.5 and 1.9 microns. AMD and CNV are prevented, delayed or reversed by using an ablative laser to ablate the sclera tissue in a predetermined patterns outside the limbus to increase the elasticity of the sclera tissue surrounding the eye globe The surgery apparatus also includes non-laser device of radio frequency wave, electrode device, bipolar device and plasma assisted device

The invention provides a human anti-vascular endothelial cell growth factor (VEGF) antibody as well as a coding gene and an application thereof. According to the invention, by virtue of genetic engineering means and a phage surface display technology, an anti-VEGF genetic engineering single-chain antibody is screened from a complete synthesis single-chain human antibody library, a variable region gene sequence of the anti-VEGF genetic engineering single-chain antibody is obtained, amino acids in a CDR (complementary determining region) of the anti-VEGF genetic engineering single-chain antibody are transformed by virtue of bioinformatics means, and finally a series of high-affinity anti-VEGF antibodies are obtained by constructing and screening mutation libraries and utilizing a chain exchange method, wherein affinity of the anti-VEGF antibodies with human VEGF is 10<-9>-10<-11>M. According to the invention, identification on immunocompetence and biological activity of the antibody is completed, the anti-VEGF antibody is verified to have the characteristic of being antagonistic to combination of VEGF and VEGFR2 and can effectively inhibit proliferation of vascular endothelial cells induced by VEGF. The invention provides a new specific candidate antibody molecule for resisting tumour and senile macular degeneration targeted by VEGF in future.

The invention relates to the technical field of medicines and in particular relates to a novel chlorine photosensitizer-pyropheophorbide-a ether amino acid derivative, a preparation method thereof and an application to preparation of antitumor medicines. A chemical structure of the pyropheophorbide-a ether amino acid derivative is shown in a general formula (I) in the specification. The pyropheophorbide-a ether amino acid derivative has the advantages of high efficiency, low toxicity and the like, and can be used for preparing new medicines for photodynamic therapy of cancers, medicines for photodynamic therapy of benign vascular diseases, such as age-related macular degeneration and nevus flammeus and medicines for photodynamic therapy of condyloma acuminate.

The current situation is such that it is difficult for drugs to reach posterior tissues of eyeball, such as choroid and retina, with the result that treating diseases in such regions is difficult. Thus, how to attain effective delivery of drugs is of importance. It has been found that effective delivery of drugs to positerior tissues of eyeball, such as choroid and retina, especially those wherein vascularization has occurred can be accomplished by systemic administration, especially intravenous administration of polymer micells having a drug incorporated therein. Further, it has been found that when a photosensitive substance is used as a drug and PDT is carried out, choroidal neo-vessels can be effectively choked so as to be useful for the treatment of age-related macular degeneration.

The present invention discloses one kind of composite soft lutein capsule and its preparation process. The content in each capsule includes lutein1-10 mg, alpha-linolenic acid 100-300 mg, vitamin A 0-5 mg and vitamin E 0-7.5 mg; and the capsule covering consists of gelatin, glycerin, water, and opacifier or edible color. The lutein is prepared through supercritical CO2 extraction process, and has no pollutant and organic solvent residue. The composite soft lutein capsule product has stable quality and high bioavailability, and has certain preventing and treating effect on senile macular degeneration, cataract and cardiac and cerebral vascular diseases.

The invention relates to novel chlorin e6 derivatives, pharmaceutically acceptable salts thereof, as well as preparation methods and applications of the novel chlorin e6 derivatives and the pharmaceutically acceptable salts and belongs to the technical field of medicines. The chlorin e6 ether amino acid derivatives comprise compounds shown as the general structural formula I and optical isomers ofthe general structural formula I. The preparation method of the novel chlorin e6 derivatives comprises steps as follows: 3-vinyl in chlorin e6 is etherified, and 15-ethylcarboxyl and amino acid are subjected to peptides formation. The chlorin e6 ether amino acid derivatives and the pharmaceutically acceptable salts thereof can be taken as photodynamic antitumor drugs for application. Compared with an existing clinically applied similar photosensitizer talaporfin, the chlorin e6 ether amino acid derivatives have the advantages of being high in photodynamic antitumor activity, high in ratio ofdark toxicity to phototoxicity and the like and can be applied to preparation of new photodynamic antitumor drugs including photodynamic cancer treating drugs, photodynamic treatment drugs for benignvascular diseases such as senile macular degeneration and nevus flammeus as well as photodynamic treatment drugs for condyloma acuminate.

The invention relates to the technical field of medicines and particularly relates to a novel chlorin photosensitizer, i.e., a chlorin p6 amino acid derivative, a preparation method therefor and use of the chlorin p6 amino acid derivative in preparation of antitumor drugs. The chlorin p6 amino acid derivative disclosed by the invention has a chemical structure represented by a general formula (I) shown in the description. The chlorin p6 amino acid derivative disclosed by the invention has the advantages of high efficiency, low toxicity and the like and can be used for preparing novel photodynamic cancer therapy drugs, drugs for photodynamic therapy on benign vascular diseases such as senile macular degeneration and nevus flammeus and drugs for photodynamic therapy on verruca acuminata.

The neuroprotective multifunctional antioxidants are compounds that contain a 2-diacetylamino-5-hydroxypyrimidine moiety, having the structural formula: wherein R1 is CH2 or C2H4; R2 is H or -OR4 where R4 is H or aryl; and R3a and R3b are independently selected from the group consisting of H and -O-alkyl. The antioxidants are orally bioavailable metal-attenuating multifunctional antioxidants that can independently attenuate transition metals, as well as scavenger free radicals. The multifunctional antioxidant compounds, by their ability to independently chelate metals, such as Fe, Cu or Zn, and scavenge free radicals generated from different sources, are neuroprotective and are beneficial for the treatment of various neurological disorders, such as Alzheimer's disease, Parkinson's disease, ALS, traumatic brain injury, ocular disorders, such as cataract, glaucoma, age-related macular degeneration and other retinal degeneration, as well as for reducing the progression of diabetic complications.

A method and system are described for controlling a therapeutic procedure performed on a patient. Based on patient-related information, control system (90) determines at least one dosage parameter and at least one application parameter of the therapeutic procedure. Display (117) displays one or more prompts instructing an operator to introduce at least one external substance into the patient in accordance with the at least one dosage parameter and displays one or more instructions to the operator to apply an output of an application device (80) to a treatment area (100) of the patient in accordance with the at least one application parameter. The therapeutic procedure may be an Indocyanine Green mediated photothrombosis treatment for age-related macular degeneration.

The invention relates to an eye health care product capable of preventing and delaying senile macular degeneration and a manufacture method. The eye health care product comprises ingredients by weight by part: 20 parts to 30 parts of chlorella extractives, 10 parts to 25 parts of kiwi fruit extractives, 15 parts to 20 parts of oyster extractives, 20 parts to 25 parts of pine bark extractives, 15 parts to 10 parts of kudzu vine root extractives and 10 parts to 15 parts of whinberry extractives. Compared with the prior art, the eye health care product capable of preventing and delaying senile macular degeneration has the advantages of effectively improving visual function, being accurate in effect and mechanism on health care function of visual function compared with other products sold in markets, and having excellent effects on preventing and curing other macular degeneration, diabetes mellitus complication fundus lesion and cataract.

A topical drug composition for the treatment of age-related maculopathy, age-rlated macular degeneration, ocular hypertension, glaucoma or other eye disease resulting from increased intraocular pressure comprising a solution of anabolic androgenic agent and 17-β-estradiol suspended or dissolved in a suitable ophthalmic vehicle is disclosed. In the preferred embodiment, 17-β-estradiol, or its esters, is in a lipid vehicle or 17-β-estradiol-3-phosphate, or other esters of 17-β-estradiol, is combined with an anabolic androgenic agent in an aqueous vehicle having a pH of between about pH 6 to pH 8. The composition is administered to the eye in an effective amount to maintain physiologic or normal intraocular pressure or to return elevated intraocular pressure to lower levels.

On the research basis that microbes of specific species are present in eyes of patients with different eye diseases, the invention discloses a method for establishing a model, and the method comprisesthe step of infecting a model carrier with the microbes. The model prepared by the method can be used for screening drugs for the eye diseases, and the eye diseases include senile macular degeneration, the behcet disease, the Vogt-Koyanagi-Harada syndrome, uveitis, retinopathy, xerophthalmia, sympathetic ophthalmia, trachoma, cataract, conjunctivitis, chalazion, glaucoma, muscae volitantes and the like.

The invention discloses a traditional Chinese medicine preparation for treating senile macular degeneration. The traditional Chinese medicine considers that senility is related to the kidney, the pupil belongs to the kidney, and the macula lutea is positioned in the center of the eye ground and belongs to spleen-earth. The senile macular degeneration comprises the clinical accompanied symptoms such as bleeding, tunica vasculosa and choroid wart and belongs to vein stagnation. The traditional Chinese medicine preparation is prepared by selecting the following traditional Chinese medicines to decoct into decoction: forestry greenstar root, Szechwan-Yunnan sanicle root, gordon euryale root, Chinese evergreenchinkapin seed, common pistache fruit, riparian greenbrier root and rhizome, Japanese Metaplexis, Chinese astilbe rhizome, yellow angledtwig magnoliavine root, sago frond and water. According to the clinical test, the traditional Chinese medicine preparation is obvious in curative effect and is worthy of clinical popularization and application.